allogene.com (ALLO): Operating Profitability

Public company logo of Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics (ALLO) is developing a scalable platform for the low-cost production of CAR-T therapies. The operating margin confirms the efficiency of this approach, where the value -4099.30 represents the current metric. Growth prospects are based on a diversified portfolio targeting various tumors and a robust patent shield, which, combined with FDA requirements, creates a significant technological barrier for competitors.

ALLO: Allogene Therapeutics, Inc. Operating Return on Sales 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Allogene Therapeutics (ALLO)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company valuation:allogene.com, ALLO
Brand item of Allogene Corp

Allogene Therapeutics (ALLO) holds a leading position in the development of off-the-shelf CAR-T products for oncology. An analysis of operating profitability allows for an assessment of cost management efficiency regarding the ALPHA platform development. This metric is calculated as the ratio of operating income to total revenue, demonstrating the portion of funds remaining after covering production costs. For the biopharmaceutical sector, this serves as an indicator of the transition from the investment phase to business scalability. Positive dynamics in this metric confirm the commercial viability of the allogeneic method.